Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings

References

• Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239–2252.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117:7121–7125.
   PubMed Web of Science ®Google Scholar
• SEER cancer statistics review, 1975–2011[Internet]. Bethesda, MD: National Cancer Institute; April 2014; [cited 2016]. Available from: http://seer.cancer.gov/csr/1975_2011/.
   Google Scholar
• Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–829.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS). Haematologica. 2011;96:1433–1440.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based prognostic scoring system (WPSS) for myelodysplastic syndromes and comparison with the revised international prognostic scoring system (IPSS-R). A study of the international working group for prognosis in myelodysplasia (IWG-PM). Leukemia. 2015;29:1502–1513.
   PubMed Web of Science ®Google Scholar
• Blau O, Blau IW. Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy. Stem Cells Cloning. 2014;7:101–108.
   PubMedGoogle Scholar
• Mufti GJ, Potter V. Myelodysplastic syndromes: who and when in the course of disease to transplant. Hematol Am Soc Hematol Educ Prog. 2012;2012:49–55.
   PubMedGoogle Scholar
• Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev. 2013;27:243–259.
   PubMed Web of Science ®Google Scholar
• Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5:e9001
   PubMed Web of Science ®Google Scholar
• Christman JK. 5-azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483–5495.
   PubMed Web of Science ®Google Scholar
• FDA approval for azacitidine – National Cancer Institute [Internet]; 2016 Jan 24]. Available from: http://www.cancer.gov/about-cancer/treatment/drugs/fda-azacitidine.
   Google Scholar
• FDA approval for decitabine – National Cancer Institute [Internet]; [2016 Jan 24]. Available from: http://www.cancer.gov/about-cancer/treatment/drugs/fda-decitabine.
   Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440.
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol. 2006;24:3895–3903.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803.
   PubMed Web of Science ®Google Scholar
• Craddock C, Quek L, Goardon N, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia. 2013;27:1028–1036.
   PubMed Web of Science ®Google Scholar
• Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 2002;3:224–229.
   PubMed Web of Science ®Google Scholar
• Santini V, Melnick A, Maciejewski JP, et al. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Crit Rev Oncol Hematol. 2013;88:231–245.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30–39.
   PubMed Web of Science ®Google Scholar
• Spange S, Wagner T, Heinzel T, et al. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol. 2009;41:185–198.
   PubMed Web of Science ®Google Scholar
• Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269:7–17.
   PubMed Web of Science ®Google Scholar
• Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361–6369.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271–3279.
   PubMed Web of Science ®Google Scholar
• Raffoux E, Cras A, Recher C, et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget. 2010;1:34–42.
   PubMed Web of Science ®Google Scholar
• Issa JP, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015;121:556–561.
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5:981–989.
   PubMed Web of Science ®Google Scholar
• Prebet T, Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2011;20:287–295.
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Gojo I, Goldberg SL, et al. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol. 2014;167:185–193.
   PubMed Web of Science ®Google Scholar
• Tan P, Wei A, Mithraprabhu S, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4:e170.
   PubMed Web of Science ®Google Scholar
• Sekeres M, Othus M, List A, et al. Additional analysis of a randomized phase II study of azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS and chronic myelomonocytic leukemia (CMML): North American intergroup study SWOG S1117. Blood. 2015;126:908.[abstract].
   Web of Science ®Google Scholar
• Sekeres M, Othus M, List A. A randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American intergroup study SWOG S1117. Blood. 2014;124:LBA–LB5.[abstract].
   Web of Science ®Google Scholar
• Garcia-Manero G, Sekeres MA, Egyed M, et al. Panobinostat plus azacitidine in adult patients with MDS, CMML, or AML: Results of a phase 2b study. Blood. 2015;126:2861.
   Google Scholar
• Garcia-Manero G, Berdeja J, Komrokji R, et al. A randomized, placebo-controlled, phase II study of pracinostat in combination with azacitidine (AZA) in patients with previously untreated myelodysplastic syndrome (MDS). Blood. 2015;126:911.[abstract].
   Web of Science ®Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US leukemia intergroup trial E1905. J Clin Oncol. 2014;32:1242–1248.
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Ketterling RP, et al. Azacitidine with or without entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 north american leukemia intergroup study. Br J Haematol. 2016;172:384–391.
   PubMed Web of Science ®Google Scholar
• Luger S, Klimek V, Cooper M, et al. Combination therapy with mocetinostat, an oral, spectrum-selective histone deacetylase (HDAC) inhibitor, and 5-azaciditine: Indication of clinical activity in MDS. Blood. 2013;122:1550.
   Web of Science ®Google Scholar
• FDA approval for lenalidomide – National Cancer Institute [Internet]; [2016 Jan 24]. Available from: http://www.cancer.gov/about-cancer/treatment/drugs/fda-lenalidomide.
   Google Scholar
• Ghosh N, Grunwald MR, Fasan O, et al. Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res. 2015;7:105–119.
   PubMed Web of Science ®Google Scholar
• Fink E. Lenalidomide induces ubiquitination and degradation of CSNK1A1 in MDS with del (5q). Abstract 4 presented at: The 56th ASH Annual Meeting; 2014 Dec 6–9; San Fracison, CA.
   Google Scholar
• Kronke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;523:183–188.
   PubMed Web of Science ®Google Scholar
• Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86–93.
   PubMed Web of Science ®Google Scholar
• Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18:113–119.
   PubMed Web of Science ®Google Scholar
• Mittelman M, Filanovsky K, Rosenbaum H, et al. Azacitidine and lenalidomide combination in higher-risk myelodysplastic syndromes-preliminary results of the vilen-01 protocol. Blood. 2013;122:1576.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Braulke F, Kundgen A, et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia. 2013;27:1403–1407.
   PubMed Web of Science ®Google Scholar
• Ades L. A phase I-II study of the efficacy and safety of lenalidomide (LEN) combined to azacitidine (AZA) in higher risk MDS and AML with del 5q- – a study by the groupe francophone des myelodysplasies (GFM). Abstract 2892 presented at: ASH 57th Annual Meeting; 2015 Dec 5–8; Orlando, FL.
   Google Scholar
• Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012;120:4945–4951.
   PubMed Web of Science ®Google Scholar
• Narayan R, Garcia JS, Percival MM, et al. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leuk Lymphoma. 2016;57:609–615.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Daver N, Jabbour E, et al. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015;2:e12–e20.
   PubMed Web of Science ®Google Scholar
• Brierley CK, Steensma DP. Thrombopoiesis-stimulating agents and myelodysplastic syndromes. Br J Haematol. 2015;169:309–323.
   PubMed Web of Science ®Google Scholar
• Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol. 2008;142:379–393.
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Beyne-Rauzy O, Braun T, et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol. 2013;92:621–631.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thepot S, Beyne-Rauzy O, et al. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk Res. 2012;36:397–400.
   PubMed Web of Science ®Google Scholar
• Boehrer S, Beyne-Rauzy O, Prebet T, et al. Interim results of A randomized phase II trial of azacitidine (AZA) +/− epo in lower risk myelodysplastic syndrome (MDS) resistant to an erythropoietic stimulating agent (ESA) alone. Blood. 2010;116:784 (ASH Annual Meeting Abstracts).
   Web of Science ®Google Scholar
• Fili C, Malagola M, Follo MY, et al. Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res. 2013;19:3297–3308.
   PubMed Web of Science ®Google Scholar
• Tobiasson M, Dybedahl I, Holm MS, et al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and int-1-risk MDS: results from the nordic NMDSG08A phase II trial. Blood Cancer J. 2014;4:e189.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Garcia-Manero G, Moore M, et al. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma. 2013;54:321–328.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010;116:3163–3170.
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120:1838–1846.
   PubMed Web of Science ®Google Scholar
• Svensson T, Chowdhury O, Garelius H, et al. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. Eur J Haematol. 2014;93:439–445.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [alliance]). Blood. 2015126:6.
   Google Scholar
• Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90:276–281.
   PubMed Web of Science ®Google Scholar
• Jilani I, Estey E, Huh Y, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118:560–566.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28:143–153.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–3254.
   PubMed Web of Science ®Google Scholar
• Daver N, Kantarjian H, Ravandi F, et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016;30:268–273.
   PubMed Web of Science ®Google Scholar
• Kung Sutherland MS, Walter RB, Jeffrey SC, et al. SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122:1455–1463.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Erba HP, Lancet JE, et al. SGN-CD33A plus hypomethylating agents: a novel, well-tolerated regimen with high remission rate in frontline unfit AML. Blood. 2015;126:454.
   PubMed Web of Science ®Google Scholar
• Hanaoka K, Suzuki M, Kobayashi T, et al. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). Int J Cancer. 1999;82:226–236.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Kadia TM, Borthakur G, et al. Pooled analysis of elderly patients with newly diagnosed AML treated with sapacitabine and decitabine administered in alternating cycles. Blood. 2015;120:2630.
   Google Scholar
• Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, et al. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling. Cell 2016;165:643–.655.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomized, controlled, phase 3 trial. Lancet Oncol. 2016;17:496–508.
   PubMed Web of Science ®Google Scholar
• Navada SC, Garcia-Manero G, Wilhelm F, et al. A phase I/II study of the combination of oral rigosertib and azacitidine in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Blood. 2014;124:3252.
   Web of Science ®Google Scholar
• Merchant A, Joseph G, Wang Q, et al. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood. 2010;115:2391–2396.
   PubMed Web of Science ®Google Scholar
• Zou J, Hong Y, Tong Y, et al. Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome. Stem Cells Int. 2015;2015:957502.
   PubMed Web of Science ®Google Scholar
• Khan AA, Harrison CN, McLornan DP. Targeting of the hedgehog pathway in myeloid malignancies: still a worthy chase? Br J Haematol. 2015;170:323–335.
   PubMed Web of Science ®Google Scholar
• Tibes R, Al-Kali A, Oliver GR, et al. The hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. J Hematol Oncol. 2015;8:114. 015-0211-8.
   PubMed Web of Science ®Google Scholar
• Tibes R, Kosiorek HE, Dueck AC, et al. Phase I/IB study of azacitidine and hedgehog pathway inhibition in myeloid malignancies. Blood. 2015;126:1347.
   Web of Science ®Google Scholar
• McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest. 2013;123:3672–3677.
   PubMed Web of Science ®Google Scholar
• Jin J, Hu C, Yu M, et al. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. PLoS One 2014;9:e100206.
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–234.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–567.
   PubMed Web of Science ®Google Scholar
• Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339:1621–1625.
   PubMed Web of Science ®Google Scholar
• DiNardo C, Stein E, Altman J, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies. Haematol eur hematol assoc annu meet 2015;100(s1):569 [abstr)]. Presented at: European Hematology Association Annual Meeting 2015;100(s1):569.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6:1796–1803.
   PubMed Web of Science ®Google Scholar
• Tamm I, Richter S, Scholz F, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J. 2004;5:489–495.
   PubMedGoogle Scholar
• Fulda S. Inhibitor of apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities. Leukemia. 2014;28:1414–1422.
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Estey EH, Borthakur G, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009;27:4741–4746.
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Herr W, Hanel M, et al. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin Lymphoma Myeloma Leuk. 2011;11:433–438.
   PubMed Web of Science ®Google Scholar
• Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42.
   PubMed Web of Science ®Google Scholar
• Wu G, Chai J, Suber TL, et al. Structural basis of IAP recognition by smac/DIABLO. Nature. 2000;408:1008–1012.
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669–681.
   PubMed Web of Science ®Google Scholar
• Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis. 2013;4:e802.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak PY, Mak DH, et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014;106:djt440.
   PubMedGoogle Scholar
• Ritchie E, Agrawal A, Patel K, et al. A phase 2 study of brinipant in combination with 5-azacitidine in patient with myelodysplastic syndrome who are naive to 5-azacitidine: a preliminary analysis of phase 2a. Abstract 2904 presented at: ASH 57th Annual Meeting; 2015 Dec 5–8; Orlando, FL.
   Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–1288.
   PubMed Web of Science ®Google Scholar
• Orskov AD, Treppendahl MB, Skovbo A, et al. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: a rationale for combined targeting of PD-1 and DNA methylation. Oncotarget. 2015;6:9612–9626.
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Luetkens T, Kloth B, et al. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol. 2011;86:918–922.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147–1152.
   PubMed Web of Science ®Google Scholar
• Emadi A, Faramand R, Carter-Cooper B, et al. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol. 2015;90:E77–E79.
   PubMed Web of Science ®Google Scholar
• Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322–3327.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–3627. quiz 3699.
   PubMed Web of Science ®Google Scholar
• Issa JP, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukemia: a multicentre, randomized, dose-escalation phase 1 study. Lancet Oncol. 2015;16:1099–1110.
   PubMed Web of Science ®Google Scholar
• Savona M. Results of first in human (FIH) phase 1 pharmacokinetic (PK) guided dose-escalation study of ASTX727, a combination of the oral cytidine deaminase inhibitor (CDAi) E7727 with oral decitabine in subjects with myelodysplastic syndrome (MDS). Abstract 1683 presented at: ASH 57th Annual Meeting; 2015 Dec 5–8; Orlando, FL.
   Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar